TargeGen

A vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target.

Launch date

2002

Employees

Market cap

Enterprise valuation

AUD865m (Public information from Jun 2010)

San Diego California (HQ)

Date	Investors	Amount	Round
May 2002	Forward Ventures Enterprise Partners	$10.0m	Series A
Jan 2004	William Blair and Company CDIB Capital Group Forward Ventures Enterprise Partners CDP Capital Technology Ventures	$30.0m	Series B
Sep 2005	William Blair and Company BB Biotech Ventures Forward Ventures Enterprise Partners	$30.0m	Series C
Jul 2007	Pappas Capital Chicago Growth Partners Hambrecht & Quist Capital Management VantagePoint Capital Partners BB Biotech Ventures CTI Life Sciences Forward Ventures Enterprise Partners CDP Capital Technology Ventures	$40.0m	Series D
Sep 2009	N/A	$3.7m	Debt
Jun 2010	Sanofi Aventis	$560m Valuation: $560m	Acquisition
Total Funding		AUD170m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about TargeGen